NADC34-like PRRSV-2 Vaccine Plasmid and Mutant Strain rBJ-VVL
Summary
Yangzhou University filed a patent application (US20260091100A1) with the USPTO for an rBJ-VVL plasmid and mutant NADC34-like PRRSV-2 strain with tropism for Marc-145 cells. The modified strain incorporates precise mutations at amino acid positions 91/97/98 of GP2a, enabling viral propagation and plaque formation in Marc-145 cells. This represents the first disclosed NADC34-like PRRSV-2-specific vaccine candidate derived from a Marc-145-adapted modified strain.
What changed
Yangzhou University (inventors: Nanhua Chen, Ming Qiu, Hong Lin, Jianzhong Zhu) filed Application US20260091100A1 disclosing an rBJ-VVL plasmid, a mutant NADC34-like PRRSV-2 strain, and a preparation method. The invention involves precise mutations at amino acid positions 91/97/98 of the GP2a protein that confer Marc-145 cell tropism, allowing the modified virus to propagate, cause cytopathic effects, form plaques, and produce high viral loads through serial passage. The resulting Marc-145-adapted modified strain serves as the foundation for a NADC34-like PRRSV-2-specific vaccine.
Entities in the swine pharmaceutical, vaccine development, and veterinary biotechnology sectors should review this application for freedom-to-operate considerations regarding NADC34-like PRRSV-2 vaccine development. Patent applications typically proceed through examination over 1-3 years; no immediate compliance action is required. The application (Application No. 19256185, filing date July 1, 2025) remains pending and has not yet been granted.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NADC34-LIKE PRRSV-2 VACCINE CANDIDATE STRAIN AND APPLICATION THEREOF
Application US20260091100A1 Kind: A1 Apr 02, 2026
Assignee
YANGZHOU UNIVERSITY
Inventors
Nanhua Chen, Ming Qiu, Hong Lin, Jianzhong Zhu
Abstract
Disclosed are an rBJ-VVL plasmid, a mutant strain of NADC34-like PRRSV-2 and a preparation method therefor and application thereof. Further disclosed is an NADC34-like PRRSV-2-specific vaccine. In the present disclosure, a modified strain rBJ-VVL with tropism for Marc-145 cells is obtained by precisely mutating an amino acid at positions 91/97/98 of GP2a; the modified virus constructed in the present disclosure can be propagated in Marc-145 cells, cause cytopathic effects and form plaques when inoculated into Marc-145 cells for serial passage; the resulting Marc-145 cell-passaged viruses have an extremely viral load, and a large number of new progeny viruses can be obtained in a short time; and the Marc-145-adapative modified strain cultured in the present disclosure is used to create a first NADC34-like PRRSV-2-specific vaccine.
CPC Classifications
A61K 39/12 A61P 37/04 C12N 7/00 C12N 15/86 A61K 2039/5252 C12N 2770/10021 C12N 2770/10034 C12N 2770/10043 C12N 2770/10051
Filing Date
2025-07-01
Application No.
19256185
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.